Healthcare / Diagnostics & ResearchNasdaqCM
$3.21
-0.13 (-3.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.0M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-339.6%
↓Gross Margin
1.2%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
-25.1%
FCF CAGR
—
FCF margin
-271.7%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.9M · net income $-10.5M · FCF $-5.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $1.9M | $1.9M | $9.3M | $9.9M | $10.4M | $11.1M | $8.2M |
| Net Income | $-10.5M | $-10.5M | $-12.5M | $-11.1M | $-10.2M | $-9.0M | $-4.7M |
| EBITDA | $-8.7M | $-8.7M | $-10.0M | $-8.8M | $-8.8M | — | — |
| EPS | -91.20 | -91.20 | -703.20 | -982.00 | -928.00 | -1672.00 | -3976.00 |
| Gross Margin | 1.2% | 1.2% | 42.9% | 51.4% | 54.3% | — | — |
| Operating Margin | -465.4% | -465.4% | -137.0% | -112.5% | -97.9% | -53.2% | -29.4% |
| Net Margin | -543.7% | -543.7% | -134.5% | -111.8% | -98.5% | -80.5% | -56.8% |
| Balance Sheet | |||||||
| Debt/Equity | 0.09 | 0.09 | 0.09 | 0.02 | 0.01 | 0.11 | — |
| Current Ratio | 0.62 | 0.62 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-5.2M | $-5.2M | $-9.0M | $-10.6M | $-9.0M | $-10.7M | $-288806.00 |
| Returns | |||||||
| ROE | -339.6% | -339.6% | -377.5% | -113.9% | -50.4% | -30.1% | 17.1% |
| Valuation | |||||||
| P/B | 0.12 | 0.12 | 0.62 | 0.56 | 0.62 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -79.2% | -79.2% | -6.4% | -4.6% | — | 36.1% | — |
| EPS Growth | 87.0% | 87.0% | 28.4% | -5.8% | — | 57.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-93.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-703.20 → -91.20
Residual
-93.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.